Actively Recruiting
Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
Led by Christian Hassager · Updated on 2024-12-20
282
Participants Needed
2
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.
CONDITIONS
Official Title
Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Resuscitated out-of-hospital cardiac arrest with a shockable first recorded heart rhythm
- Mean arterial pressure greater than 40 mmHg
- Decision made to perform prehospital intubation
You will not qualify if you...
- Met advanced life support termination-of-resuscitation criteria
- Systolic blood pressure greater than 190 mmHg
- Known allergy to ketamine or propofol
- Chronic diseases making 180-day survival unlikely
- Body temperature below 30 degrees Celsius
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Cardiology, Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
2
Odense University Hospital
Odense C, Denmark, 5000
Not Yet Recruiting
Research Team
S
Salma Charabi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here